Thermedical, a Waltham, Mass.-based medical equipment company developing new tissue-ablation therapies, completed a $5.5m Series A2 financing.
The round was led by Samuel H. Maslak, Sc.D. and Karl H. Johannsmeier, with participation from angel investors.
The company intends to use the funds to hire technical staff, continue funding research into the ablation of solid tumors and ventricular tachycardia, and begin first-in-man studies later this year.
Founded by Massachusetts Institute of Technology (MIT) Hyperthermia Center alumni Michael G. Curley, Ph.D. and Patrick S. Hamilton, Ph.D., Thermedical has developed thermal-ablation systems to treat cancer and cardiac arrhythmias.
It received U.S. Food & Drug Administration (FDA) clearance for its technology for the coagulation and ablation of soft tissue during percutaneous, laparoscopic, and intraoperative surgical procedures in October 2012.